Starting a medtech company comes with a host of challenges, from regulation to financing to reimbursement. One way that companies can overcome those challenges, according to 2 industry experts, is to outsource some of the research and development work – and in the process, create a leaner, more flexible company.
Financing for medtech startups can still be found, but the market climate is less than ideal, panelists at a LifeScience Alley conference said this week in Minneapolis.
The panel, "Financing Opportunities in Today’s Marketplace," discussed venture capital, IPOs, strategic investors and the important role played by a board of directors play.
With 2014 a rebounding year for medical device and biopharmaceutical IPOs, 2015 should build further on that progress, a panel at the MedTech Investing Conference said this week.
When it comes to policy issues, it was good news/bad news for attendees of the 2015 MedTech Investing Conference in Minneapolis.
After an off-the-charts year in investment for 2014, the Minnesota bioscience industry has seen a more typical 1st quarter, according to a report from medtech lobby LifeScience Alley.
LifeScience Alley, the Minneapolis-based trade association of medical device and life science companies, has chosen a new board chair and made other changes to its board of directors.
Investment in Minnesota’s thriving medtech scene hit a 6-year high in 2014 and the state saw a significant jump in pharma/biotech investments, according to LifeScience Alley’s annual report.
Medical device manufacturers are facing a shrinking number of buyers and an increasingly sophisticated healthcare world, in which Twitter and Facebook may spread word of their products more swiftly than any marketing campaign.
MassDevice Network
@MassDevice
LinkedIn
YouTube